Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for the DIY PC market, beginning with the NT-CP1 AM5/4 for AMD Ryzen™ processors ATLANTA, June 1, 2026 /PRNewswire/ — Carbice, a U.S.-based developer and supplier of next-generation carbon nanotube thermal interface materials (TIMs) and high-performance cooling solutions, today announced a long-term strategic partnership […]

The Carbice Ice Pad provides a reliable, peel-and-stick, maintenance-free thermal paste alternative designed for consistent gaming performance over the life of a system Partnership marks the first time consumers can experience advanced carbon nanotube CPU cooling through a mainstream retail CPU provider ATLANTA, June 1, 2026 /PRNewswire/ — Carbice, a U.S.-based developer and supplier of next-generation carbon […]

Exploring New Business Opportunities with Global Buyers TAIPEI, June 1, 2026 /PRNewswire/ — The New Taipei City Government is leading a delegation of 20 companies specializing in smart manufacturing, automation, industrial AI, and key components to participate in AUTOMATE 2026, one of North America’s leading trade shows for automation and robotics, held in Chicago, USA. […]

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned. […]

IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR of 100% The second stage of the PoC study is ongoing […]

SUZHOU, China, June 1, 2026 /PRNewswire/ — ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off on January 31, 2026, the optimized dose of MVR-T3011 achieved a 100% […]

SHANGHAI, June 1, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line (1L) treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma […]

First-line NSCLC – Compelling Activity Across All PD-L1 SubgroupsIn first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low  population (TPS ≤5%) […]